成人2型糖尿病药物:动态系统评价与网络Meta分析
该动态系统评价与网络Meta分析纳入869项随机对照试验、493168例成人2型糖尿病患者,评估13类63种药物的获益与危害。中至高确定性证据证实SGLT-2抑制剂、GLP-1受体激动剂和非奈利酮的心肾获益;替尔泊肽和奥福格列酮减重最显著;各药物有特异性危害。
要点
- 中至高确定性证据证实SGLT-2抑制剂、GLP-1受体激动剂和非奈利酮(用于已确诊慢性肾病患者)的心血管和肾脏获益。
- 减重最有效的药物为替尔泊肽(平均差-8.63 kg,95%CI -9.34至-7.93;中等确定性)和奥福格列酮(平均差-7.87 kg,95%CI -10.24至-5.50;低确定性)。
- SGLT-2抑制剂增加生殖器感染(OR 3.29,95%CI 2.88至3.77;高确定性)和糖尿病酮症酸中毒(OR 2.08,95%CI 1.45至2.99;高确定性),可能增加截肢(OR 1.27,95%CI 1.01至1.61;中等确定性)。
核心结论
- 该动态系统评价全面总结了成人2型糖尿病药物在心肾获益和减重方面的效果及药物特异性危害,涵盖SGLT-2抑制剂、GLP-1受体激动剂、非奈利酮和替尔泊肽等。
研究设计与样本
- 动态系统评价与网络Meta分析,采用频率学随机效应模型和GRADE方法,计划每年至少更新两次。
- 检索Medline和Embase至2024年7月31日,纳入至少24周的随机对照试验,比较一种或多种药物与标准治疗、安慰剂或彼此。
- 共纳入869项试验、493168例参与者(自2022年10月以来新增53项试验),报告13类药物(63种药物)和26个结局的数据。
主要发现
- 中至高确定性证据证实SGLT-2抑制剂、GLP-1受体激动剂和非奈利酮(用于已确诊慢性肾病患者)的心血管和肾脏获益。
- 减重最有效的药物为替尔泊肽(平均差-8.63 kg,95%CI -9.34至-7.93;中等确定性)和奥福格列酮(平均差-7.87 kg,95%CI -10.24至-5.50;低确定性),随后为其他八种GLP-1受体激动剂(高至中等确定性)。
- SGLT-2抑制剂增加生殖器感染(OR 3.29,95%CI 2.88至3.77;高确定性)和糖尿病酮症酸中毒(OR 2.08,95%CI 1.45至2.99;高确定性),可能增加截肢(OR 1.27,95%CI 1.01至1.61;中等确定性)。
- 替尔泊肽和GLP-1受体激动剂可能增加严重胃肠道事件(替尔泊肽风险增加最多,OR 4.21,95%CI 1.87至9.49;中等确定性);非奈利酮增加严重高钾血症(OR 5.92,95%CI 3.02至11.62;高确定性);噻唑烷二酮类增加主要骨质疏松性骨折,可能增加心力衰竭住院。
- 磺脲类、胰岛素和二肽基肽酶-4抑制剂可能增加严重低血糖风险;GLP-1受体激动剂是否减少痴呆尚不确定(OR 0.92,95%CI 0.83至1.02;低确定性)。
关键数值与推荐
- SGLT-2抑制剂:生殖器感染OR 3.29(95%CI 2.88至3.77;高确定性),糖尿病酮症酸中毒OR 2.08(95%CI 1.45至2.99;高确定性),截肢OR 1.27(95%CI 1.01至1.61;中等确定性)。
- 替尔泊肽:减重平均差-8.63 kg(95%CI -9.34至-7.93;中等确定性);严重胃肠道事件OR 4.21(95%CI 1.87至9.49;中等确定性)。
- 奥福格列酮:减重平均差-7.87 kg(95%CI -10.24至-5.50;低确定性)。
- 非奈利酮:严重高钾血症OR 5.92(95%CI 3.02至11.62;高确定性)。
- GLP-1受体激动剂与痴呆:OR 0.92(95%CI 0.83至1.02;低确定性)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide up-to-date evidence on key benefits, harms, and uncertainties regarding medications for adults with type 2 diabetes. DESIGN: Living systematic review and network meta-analysis (NMA), using frequentist random effects and GRADE (grading of recommendations, assessment, development and evaluation) approaches. Updates are planned at least two times a year. DATA SOURCES: Medline and Embase, searched up to 31 July 2024 for the current iteration. STUDY SELECTION: Randomised controlled trials of at least 24 weeks comparing one or more medications with standard treatment, placebo, or each other. RESULTS: The systematic review and NMA includes 493 168 participants from 869 trials (adding 53 trials since October 2022) reporting data for 13 drug classes (63 drugs) and 26 outcomes of interest. Regarding benefits, moderate to high certainty evidence confirms the well established cardiovascular and kidney benefits of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and finerenone (the last for patients with established chronic kidney disease). The most effective drugs in reducing body weight were tirzepatide (mean difference (MD) -8.63 kg (95% confidence interval -9.34 to -7.93); moderate certainty) and orforglipron (MD -7.87 kg (-10.24 to -5.50); low certainty), followed by eight other GLP-1RAs (high to moderate certainty). Absolute benefits of medications vary substantially depending on the baseline risk of cardiovascular and kidney outcomes; risk-stratified absolute effects of medications are summarised using an interactive multiple comparisons tool (https://matchit.magicevidence.org/250709dist-diabetes/#!/). Regarding medication-specific harms, SGLT-2 inhibitors increase genital infections (odds ratio (OR) 3.29 (95% CI 2.88 to 3.77); high certainty) and ketoacidosis due to diabetes (OR 2.08 (1.45 to 2.99); high certainty), and probably increase amputations (OR 1.27 (1.01 to 1.61); moderate certainty); tirzepatide and GLP-1RAs probably increase severe gastrointestinal events (most increased risk with tirzepatide (OR 4.21 (1.87 to 9.49); moderate certainty)); finerenone increases severe hyperkalaemia (OR 5.92 (3.02 to 11.62); high certainty); and thiazolidinediones increase major osteoporotic fractures and probably increase hospitalisation for heart failure. Sulfonylureas, insulin, and dipeptidyl peptidase-4 inhibitors probably increase the risk of severe hypoglycaemia. There is low to very low certainty evidence for effects on other diabetes-related complications, including neuropathy and visual impairment. Despite interest in the issue, there is uncertainty about whether GLP-1RAs may reduce dementia (OR 0.92 (0.83 to 1.02); low certainty). CONCLUSIONS: This living systematic review provides a comprehensive summary of the cardiovascular, kidney, and weight loss benefits, as well as medication-specific harms of medications for adults with type 2 diabetes, including effects of SGLT-2 inhibitors, GLP-1RAs, finerenone and tirzepatide. SYSTEMATIC REVIEW REGISTRATION: PROSPERO number: CRD42022325948. A more detailed protocol is available at https://data.aliveevidence.org/records/q02rv-km486. READERS' NOTES: This article is the first version of a living systematic review. It is linked to a living BMJ Rapid Recommendation and other living clinical practice guidelines, presenting risk stratified recommendations for patients with type 2 diabetes at lower, moderate, and higher risk of cardiovascular and kidney complications. The latest evidence will be made available via the BMJ Rapid Recommendation and via an interactive GRADE evidence summary (MATCH-IT: https://matchit.magicevidence.org/250709dist-diabetes/#!/). Major updates will be published in The BMJ.
引用
- Nong K, Jeppesen BT, Shi Q, et al. Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis. BMJ. 2025. PMID: 40813122. doi:10.1136/bmj-2024-083039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。